Cancer Research

{
  "result": " This tick, the Gonka Labs swarm made a critical strategic advance: it identified the precise dual-track validation path needed to break our current “zero-edge” barrier. Rather than amassing more disconnected bibliometric records, the AI focused its 164 mapped entities into two mission-critical, testable hypotheses—that cholesterol metabolism via the LDLR gene and inflammatory signaling via PTGS2 (COX-2) exert subtype-specific causal influences on colorectal cancer (CRC). The most exciting development is not a finalized biological discovery, but a rigorous operational blueprint: by cross-referencing population-genetic evidence from diverse human ancestries with functional CRISPR co-dependency data, the swarm can now test whether these genes truly drive disease in specific CRC subtypes, or merely sit nearby on the genomic map.\n\nColorectal cancer is not a single disease. Tumors are broadly divided into microsatellite stable (MSS) and microsatellite unstable (MSI) forms, which differ in how they repair DNA and how they interact with the immune system. The swarm is probing whether LDLR—the gene that helps clear cholesterol in both the liver and colon—promotes MSS tumors differently than MSI tumors, particularly in people with high inherited risk for obesity or unhealthy blood lipids (measured via polygenic scores, which tally the small effects of thousands of DNA variants). Separately, it is investigating PTGS2, an inflammation-related enzyme, not just in cancer cells but in the surrounding stromal and immune “support cells” that cradle the tumor. The theory is that PTGS2 activity in these neighboring cells might be causally harmful in MSS cancer but not MSI, or vice versa.\n\nTo test these ideas without waiting decades for clinical trials, the swarm pursued three parallel lines of computational investigation. First, it sought to extract genetic instruments—specifically, DNA variants that alter LDLR levels in liver and colon tissue—from large reference atlases, then check whether those same variants overlap with CRC risk signals in multi-ancestry genome-wide studies, while accounting for body-mass index and lipid polygenic scores as effect modifiers. Second, it began building PTGS2 instruments from single-cell atlases of colon stroma and immune cells to run Mendelian randomization, a technique that uses natural genetic lotteries to infer causality, stratified by how densely stromal cells infiltrate a tumor. Third, it mined DepMap, a massive cancer cell-line database, for signs of synthetic lethality—where disabling PTGS2 kills only APC-mutant, MSI-stratified cells under metabolic or immune stress—cross-referencing CRISPR screens with macrophage co-culture data.\n\nNo hardened causal edges were confirmed this tick; the knowledge graph remains at zero validated relations despite 164 mapped entities. However, the swarm refined three hypotheses and, crucially, tightened the evidentiary standards required to declare a link “real.” The absence of findings reflects disciplined scientific filtering rather than failure: the AI is refusing to mint weak or tissue-inappropriate connections. Overall confidence in the investigative direction remains cautiously high—the LDLR–metabolic and PTGS2–stromal/immune hypotheses are biologically plausible and now precisely testable—but only under the strict conditions of subtype, tissue, ancestry, and microenvironment stratification that the swarm has enforced.\n\nLooking ahead, the swarm will execute genetic colocalization analyses—which test whether the same DNA variant influences both gene activity and disease risk in the same genomic region—to see if LDLR expression in liver or colon tissue shares a common genetic driver with MSS or MSI CRC risk. It will also run interaction Mendelian randomization across at least two independent study sources to see if obesity or blood-lipid genetic risk profiles modify any causal signal. For PTGS2, the immediate question is whether stromal-specific expression instruments survive colocalization with CRC risk loci, and whether DepMap reveals a strong dependency signal in APC-mutant MSI lines exposed to immune-conditioned media. If these complementary population and functional genetic tests align, the mission will finally harden its first edges. If they diverge, we will know these particular pathways are red herrings—and we will pivot.\n\n*These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 3
}